AB家的NGL相关资料.docVIP

翻译Abbott Laboratories (ABT) Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients?7/22/2009检测尿中中性粒细胞明胶酶相关载脂蛋白有望监测心脏移植者环孢霉素毒性7/22/2009CHICAGO, July 22 /PRNewswire-FirstCall/ -- Research presented at the American Association for Clinical Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant patients with the Urine NGAL assay on Abbotts ARCHITECT immunoassay analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to prevent possible irreversible kidney damage.?芝加哥，7月22日/美通社/-从今天召开的美国临床化学协会（AACC）年度会议的研究结果发表得知采用雅培ARCHITECT?免疫分析仪检测尿中中性粒细胞明胶酶相关载脂蛋白可能有助于临床医生检测心脏移植患者环孢霉素诱导的毒性，以及调节环孢霉素剂量以预防其对肾脏造成的不可逆伤害。In a scientific poster presented at AACC today by researchers at the University of Toronto, eleven heart transplant patients were treated with anti-rejection drug combinations and monitored with the Urine NGAL assay within twelve hours of administration. The study concluded that Urine NGAL monitoring may be able to assist in the detection of chronic cyclosporine-induced toxicity in the kidneys following heart transplant procedures.?今天AACC上的加拿大多伦多大学的研究者一份科学海报介绍：11名心脏移植患者采用抗排斥的药物组合处理并在给药12小时内监测尿中中性粒细胞明胶酶相关载脂蛋白。研究结论是心脏移植患者尿中中性粒细胞明胶酶相关载脂蛋白浓度的监测有可能有助于发现慢性环孢霉素诱导肾毒性。Abbott is currently developing an assay to measure NGAL (neutrophil gelatinase-associated lipocalin) concentrations in urine for use on the companys flagship automated laboratory instrument, the ARCHITECT system. Abbott has rights to commercialize Urine NGAL for renal diagnostic applications and is expected to introduce the product in Europe in late 2009. The assay is not available in the United States. NGAL is a small, robust protein produced by the kidney tubules and appears in urine just two-to-four hours following acute kidney injury (AKI), up to 46 hours sooner than current test methods.?雅培目前正在研发一种检测尿中中性粒细胞明胶酶相关载脂蛋白浓度的检测方法，该方法在公司旗舰产品——ARCHITECT system——自动实验室设备。雅培